Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06124625
Other study ID # Reload 2.0
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date January 31, 2024
Est. completion date February 28, 2025

Study information

Verified date March 2024
Source Schön Klinik Berchtesgadener Land
Contact Inga Jarosch, DR
Phone +498652-93
Email ijarosch@schoen-klinik.de
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Infection with SARS-CoV-2 virus leads to persistent symptoms for more than 12 weeks in 15% of cases ("post-COVID syndrome"). Symptoms like fatigue, dyspnoea, limitations in physical performance and activities, head ache, anxiety symptoms, and depression are heterogenous which limit physical health and participation in daily life activities. In the last years, multidisciplinary rehabilitation programs showed benefits in quality of life and symptom intensity in patients with post-COVID. Therefore, rehabilitation programs are recommended for individuals with Post-COVID by official sites like the German Society of Pulmonology and the European Respiratory Society. Own first data (published at the ERS conference 2023) revealed that one the one hand, inpatient rehabilitation is effective, however, on the other hand, it is challenging to maintain these effects after completing the program. Therefore, the aim of this study is to sustain these benefits by using a digital maintenance program following the rehabilitation program compared to usual care.


Recruitment information / eligibility

Status Recruiting
Enrollment 90
Est. completion date February 28, 2025
Est. primary completion date December 30, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Post-COVID-syndrome (Definition WHO) - Entered the rehabilitation process at the Schoen Klinik Berchtesgadener Land Exclusion Criteria: - No internet access

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Rehabilitation combined to a digital maintenance program
Individuals in this group undergo a 3-week inpatient rehabilitation program followed by a 12-week maintenance program (2 sessions per week à 90 minutes, digital and live). The multimodal programs consist of physiotherapy, training therapy, medical support, cognitive training, education and psychological support.
Rehabilitation without maintenance program
Individuals in this group undergo a 3-week inpatient rehabilitation program followed by a 12-week usual care period.

Locations

Country Name City State
Germany Schone Klinik Berchtesgadener Land Schönau Am Königssee

Sponsors (4)

Lead Sponsor Collaborator
Schön Klinik Berchtesgadener Land Bavarian State Ministry of Health and Care (Funding), Betriebskrankenkassen Landesverband Bayern (Bavarian health insurance) (Design), Deutsche Rentenversicherung (German pension insurance)

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from baseline quality of life assessed by Short-Form 12 questionnaire at week 4 and week 19 The scale of the physical and mental Health component summary score ranges from minimum 0 to maximum 100 points with higher scores indicating better quality of life Baseline, week 4, week 19
Secondary Change from baseline post-COVID-related symptoms at week 4 and week 19 The number of COVID-symptoms will recorded as well as their intensity will be rated on a scale from 0 [not relevant] until 10 [very severe symptom]. Baseline, week 4, week 19
Secondary Change from baseline lung function at week 4 and week 19 following Parameters will be collected:Pimax Baseline, week 4, week 19
Secondary Change from baseline fatigue symptoms at week 4 and week 19 Fatigue Assessment Scale will be used Baseline, week 4, week 19
Secondary Change from baseline exercise capacity at week 4 and week 19 1-minute sit to stand test will be performed (maximum repetitions of squats in one minute) Baseline, week 4, week 19
Secondary Change from baseline physical activity at week 4 and week 19 Activity will be measure in steps per day using a wearable from Polar Baseline, week 4, week 19
Secondary Change from baseline quality of life at week 4 and week 19 EQ-5D-5L questionnaire will be used. Baseline, week 4, week 19
Secondary Change from the use of health care service at week 4 and week 19 Frequency of therapeutical, medical and psychological sessions will be documented. Baseline, week 4, week 19
Secondary Change from the use of medications at week 4 and week 19 Amount and kind of medication will be documented. Baseline, week 4, week 19
Secondary Change from rate of sickness at week 4 and week 19 Days of sickness will be documented. Baseline, week 4, week 19
Secondary Change from workability at week 4 and week 19 Work ability index will be used Baseline, week 4, week 19
Secondary Change from ICF functionality at week 4 and week 19 Indicators of rehabilitation status questionnaire (IRES-3) will be used. Baseline, week 4, week 19
Secondary Change from sleep quality at week 4 and week 19 Sleep quality will be assessed by using the Pittsburgh Sleep Quality Index (total score ranges from 0 to 21 with higher scores indicating higher impairment) Baseline, week 4, week 19
Secondary Change from depression symptoms at week 4 and week 19 Patient Health Questionnaire 9 will be used. The total score ranges from 0 to 27 points with higher scores indicating worse Depression symptoms Baseline, week 4, week 19
Secondary Change from anxiety symptoms at week 4 and week 19 Generalized Anxiety Disorder Scale 7 will be used. The total score ranges from 0 to 21 points with higher scores indicating more anxiety symptoms Baseline, week 4, week 19
Secondary Change from resilience at week 4 and week 19 Resilience scale RS-13 will be used. Baseline, week 4, week 19
Secondary Change from cognition at week 4 and week 19 Cognition will be measured via the software RehaCom (by Hasomed GmbH). Baseline, week 4, week 19
Secondary Change from cognitive impairment at week 4 and week 19 Cognitive impairment will be measured by Montreal Cognitive Assessment (MoCA) Baseline, week 4, week 19
See also
  Status Clinical Trial Phase
Recruiting NCT06073002 - Effects of a Home-Based Exercise Intervention in Subjects With Long COVID N/A
Completed NCT05047952 - Vortioxetine for Post-COVID-19 Condition Phase 2
Completed NCT05812209 - Stellate Ganglion Block to Treat Long COVID 19 Case Series
Recruiting NCT06091384 - Inspiratory Muscle Strength Training in Post-Covid Syndrome N/A
Not yet recruiting NCT06267300 - Treatment of Post-COVID-19 With Hyperbaric Oxygen Therapy: a Randomized, Controlled Trial Phase 3
Recruiting NCT05986422 - Methylprednisolone in Patients With Cognitive Deficits in Post-COVID-19 Syndrome (PCS) Phase 2
Not yet recruiting NCT05534997 - Rehabilitation Therapy for Post COVID 19 Chronic Fatigue Syndrome N/A
Recruiting NCT05638633 - Prednisolone and Vitamin B1/6/12 in Patients With Post-Covid-Syndrome Phase 3
Active, not recruiting NCT05630040 - VNS for Long-COVID-19 N/A
Recruiting NCT05841498 - Immunoadsorption Study Mainz in Adults With Post-COVID Syndrome N/A
Enrolling by invitation NCT05981872 - EFFECT OF COGNITIVE BEHAVIORAL THERAPY ON DEPRESSION AND QUALITY OF LIFE IN PATIENTS WITH POST COVID-19 N/A
Active, not recruiting NCT05543408 - Long COVID-19 Syndrome in Primary Care: A Novel Protocol of Exercise Intervention "CON-VIDA Clinical Trial" N/A
Recruiting NCT05817032 - Effect of Telerehabilitation Practice in Long COVID-19 Patients N/A
Recruiting NCT05823896 - imPROving Quality of LIFe In the Long COVID Patient Phase 2
Completed NCT05764070 - Impact of Vagus Nerve Stimulation on Post-Aerobic Activity Recovery in Post SARS-CoV-2 Patients N/A
Completed NCT05765591 - Balneotherapy for Patients With Post-acute Coronavirus Disease (COVID) Syndrome N/A
Recruiting NCT05918965 - Vagus Stimulation in Female Long COVID Patients. N/A
Not yet recruiting NCT06231238 - Balance Acceptance and Commitment Therapy for Long COVID Phase 2
Completed NCT06282627 - The COVID HOME Study: Prospective Cohort Study of Non-hospitalised COVID-19 Patients
Completed NCT05648734 - Anti-Inflammatory and Anti-Fibrotic Drugs in Post COVID-19 Pulmonary Fibrosis